Cohn DE - Search Results

1

Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.

Barrington DA, Riedinger C, Haight PJ, Tubbs C, Cohn DE. Barrington DA, et al. Among authors: cohn de. Gynecol Oncol. 2022 Jun;165(3):500-505. doi: 10.1016/j.ygyno.2022.03.031. Epub 2022 Apr 12. Gynecol Oncol. 2022. PMID: 35422338

2

Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?

Cohn DE, Horowitz NS, Mutch DG, Kim SM, Manolitsas T, Fowler JM. Cohn DE, et al. Gynecol Oncol. 2002 Dec;87(3):243-6. doi: 10.1006/gyno.2002.6825. Gynecol Oncol. 2002. PMID: 12468320

3

Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies.

Wright JD, Herzog TJ, Mutch DG, Gibb RK, Rader JS, Davila RM, Cohn DE. Wright JD, et al. Among authors: cohn de. Gynecol Oncol. 2003 Oct;91(1):134-8. doi: 10.1016/s0090-8258(03)00509-2. Gynecol Oncol. 2003. PMID: 14529673

4

Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer?

Lindauer J, Fowler JM, Manolitsas TP, Copeland LJ, Eaton LA, Ramirez NC, Cohn DE. Lindauer J, et al. Among authors: cohn de. Gynecol Oncol. 2003 Dec;91(3):547-51. doi: 10.1016/j.ygyno.2003.08.003. Gynecol Oncol. 2003. PMID: 14675674

5

The role of MRI in the conservative management of endometrial cancer.

Ben-Shachar I, Vitellas KM, Cohn DE. Ben-Shachar I, et al. Among authors: cohn de. Gynecol Oncol. 2004 Apr;93(1):233-7. doi: 10.1016/j.ygyno.2004.01.031. Gynecol Oncol. 2004. PMID: 15047242 Review.

6

Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins.

Cohn DE, Morrison CD, Zanagnolo VL, Goist MM, Copeland LJ. Cohn DE, et al. Gynecol Oncol. 2005 Jul;98(1):158-60. doi: 10.1016/j.ygyno.2005.04.013. Gynecol Oncol. 2005. PMID: 15913738

7

The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).

Dietrich CS 3rd, Modesitt SC, DePriest PD, Ueland FR, Wilder J, Reedy MB, Pavlik EJ, Kryscio R, Cibull M, Giesler J, Manahan K, Huh W, Cohn D, Powell M, Slomovitz B, Higgins RV, Merritt W, Hunter J, Puls L, Gehrig P, van Nagell JR Jr. Dietrich CS 3rd, et al. Gynecol Oncol. 2005 Dec;99(3):557-63. doi: 10.1016/j.ygyno.2005.07.104. Epub 2005 Sep 8. Gynecol Oncol. 2005. PMID: 16154185

8

Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.

Estes JM, Leath CA, Williams S, Modiano MR, Sawyer M, Cohn D, Straughn JM, Barnes MN, Alvarez RD. Estes JM, et al. Gynecol Oncol. 2006 Aug;102(2):338-42. doi: 10.1016/j.ygyno.2005.12.031. Epub 2006 Feb 20. Gynecol Oncol. 2006. PMID: 16487997 Clinical Trial.

9

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.

Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Cohn DE, et al. Gynecol Oncol. 2006 Aug;102(2):134-9. doi: 10.1016/j.ygyno.2006.01.030. Epub 2006 Mar 9. Gynecol Oncol. 2006. PMID: 16527339

10

Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer.

Burkett AM, Cohn DE, Copeland LJ. Burkett AM, et al. Among authors: cohn de. Gynecol Oncol. 2007 Feb;104(2):491-3. doi: 10.1016/j.ygyno.2006.10.029. Epub 2006 Dec 5. Gynecol Oncol. 2007. PMID: 17150244

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

331 results

Search Page

Filters